Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine anti-tumor activity by measuring overall response
rate in recurrent and/or metastatic HNSCC patients receiving the combination of metformin and
pembrolizumab.